Aurinia Pharmaceuticals (AUPH) has released an update.
Aurinia Pharmaceuticals announced that the FDA has approved an updated label for LUPKYNIS to include three-year data from the AURORA clinical trials, indicating sustained renal response in lupus nephritis patients. The updated guidance also simplifies kidney function monitoring to quarterly checks after the first year, aligning with standard care practices. The safety profile of LUPKYNIS remains consistent with previous findings.
For further insights into AUPH stock, check out TipRanks’ Stock Analysis page.
